ArticleJournal of medical biochemistry2019
A Novel Biomarker Renalase and Its Relationship with its Substrates in Schizophrenia.
Article in Journal of medical biochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Article
- Relationship between renal function and cognitive impairment in patients with stable schizophrenia: a multicenter cross-sectional study.BMC psychiatry · 2025Article
- Exploring the genetics of lithium response in bipolar disorders.International journal of bipolar disorders · 2024Article
- Exploring the genetics of lithium response in bipolar disorders.Research square · 2023Article
- Epigenetic Targets in Schizophrenia Development and Therapy.Brain sciences · 2023Review
- Consensus on potential biomarkers developed for use in clinical tests for schizophrenia.General psychiatry · 2022Article
- Actualities in immunological markers and electrochemical sensors for determination of dopamine and its metabolites in psychotic disorders (Review).Experimental and therapeutic medicine · 2021Review
- Article
- Interaction of apelin, elabela and nitric oxide in schizophrenia patients.Journal of medical biochemistry · 2020Article
- Platelet glutamate dehydrogenase activity and efficacy of antipsychotic therapy in patients with schizophrenia.Journal of medical biochemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia, particularly the form related to excessive dopamine (DA), is a chronic psychotic disorder affecting millions of people worldwide. Renalase metabolizes its catecholamine (CA) substrates, including DA, suggesting that there might be an association between renalase levels and schizophrenia occurrence. Therefore, the current study aimed to evaluate the renalase and CA levels in the serum of patients with schizophrenia.
methodsThe study was conducted with thirty-three schizophrenia patients and an age- and gender-matched group of thirty-one controls. Renalase and CA levels were measured by using an enzyme-linked immunosorbent assay (ELISA).
resultsRenalase levels were significantly lower in the schizophrenia patients than in the control group (
conclusionsThe high DA levels in patients with schizophrenia might be due to low renalase levels. Renalase enzyme levels may play a substantial role in the pathophysiology of schizophrenia. Thus, this enzyme might be a new future target for the treatment and diagnosis of schizophrenia after intrabrain renalase and DA dynamics have been further evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.